Locus Biosciences

@LocusBio

Next generation CRISPR technology for programmed cell death. Focused on developing therapies for infectious disease and the microbiome.

RTP, North Carolina
Vrijeme pridruživanja: svibanj 2013.

Tweetovi

Blokirali ste korisnika/cu @LocusBio

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @LocusBio

  1. 9. sij

    Locus is proud to announce the start of its first clinical trial. See the full announcement at

    Poništi
  2. 12. stu 2019.

    We’ve been named to ’s list of the 100 most promising startup companies in the world! Learn why CNBC thinks we’re on the way to becoming a household name:

    Poništi
  3. 26. ruj 2019.

    Locus co-founders Charles Gersbach and Rodolphe Barrangou were recognized for their groundbreaking work applying Type I CRISPR systems to eukaryotic cells.

    Poništi
  4. 23. ruj 2019.

    Locus is honored to be named to the 2019 by . We appreciate Fierce's recognition of our hard work to address unmet medical needs in and diseases using .

    Poništi
  5. 23. ruj 2019.

    Locus is honored to be named to the 2019 by . We appreciate Fierce's recognition of our hard work to address unmet medical needs in and diseases using .

    Poništi
  6. 23. svi 2019.

    We are honored to be recognized as Company of the Year by

    Poništi
  7. 22. svi 2019.

    Thanks and for excellent story on Locus enhanced therapies for treating bacterial infections. We are excited to try to help heroes like Mr. Evans.

    Poništi
  8. proslijedio/la je Tweet
    26. ožu 2019.

    Great talk from Dave Ousterout of on their -Cas3-phage platform. They’re enrolling for an E. coli clinical trial against UTIs & are excited to move toward editing in the future.

    Poništi
  9. 20. sij 2019.

    is hiring! Open positions in business development, preclinical research, clinical development, and cGMP manufacturing of enhanced products. Join the fight against and the hunt for therapies at .

    Poništi
  10. 17. sij 2019.

    Locus Biosciences Introducing crPhage: via

    Poništi
  11. 16. sij 2019.

    Thanks for the fantastic article - we're proud to be part of the fight using and thrilled to have back us. Antibiotics Are Failing Us. Crispr Is Our Glimmer of Hope

    Poništi
  12. 8. sij 2019.

    Did you know there are many types of other than Cas9? See how uses to eliminate with

    Poništi
  13. 3. sij 2019.

    Locus Biosciences is proud to announce a $818M collaboration with to develop precision therapeutics for critical needs respiratory infections. Read the press release here:

    Poništi
  14. 3. sij 2019.

    What is ? Check out how is changing the fight against by utilizing the power of and the specificity of

    Poništi
  15. 19. pro 2018.
    Poništi
  16. 17. pro 2018.

    Introducing crPhage™, a breakthrough innovation leveraging to safely and precisely eliminate harmful bacteria in the . Learn more:

    Poništi
  17. 29. stu 2018.

    We're proud to be selected Best Initial Venture Funding and to be recognized alongside fellow companies , , , Humacyte, Tellus Therapeutics, NeuroTronik, , and EternaTear.

    Poništi
  18. 26. lis 2018.

    Big thank you to for recognizing as a finalist for an SEBIO Award in the Initial Venture Funding category. Winners to be announced Nov-14 in Atlanta.

    Poništi
  19. proslijedio/la je Tweet
    9. lis 2018.

    It is a pleasure to welcome panelists from , , , , , and the @ContraFectCorporation for their Keynote Panel on the first day of

    Poništi
  20. proslijedio/la je Tweet
    2. lis 2018.
    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·